breast cancer, AstraZeneca

US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Considering Sacituzumab in HR+, HER2- Breast Cancer After Progression
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic breast cancer who had progressed on multiple line of therapy.
Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Women on Medicaid at Higher Risk of Breast Cancer
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
Huge real-world test shows AI can help identify breast cancer
Technology could soon do more than assist doctors. Thanks to advancements in cancer-identifying AI, it could actively save ...
Inside Edition Reporter Undergoes Double Mastectomy After Discovering Breast Cancer on Assignment
Inside Edition' reporter Alison Hall undergoes a double mastectomy, after discovering her breast cancer while on assignment.
Danielle Fishel opens up about breast cancer battle: 'It hurts to live right now'
"Boy Meets World" star Danielle Fishel said she is finished with radiation treatment for cancer and opened up about the side ...
Healthline5d
What Does Breast Cancer Look Like?
If you have breast cancer, you will have changes in your breast. These may be lumps or changes in the size or color of your breast, or changes in the appearance of your nipples. Breast cancer ...
Medscape1d
Breast Cancer Screening at 40 Seems Cost-Effective in Canada
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Us Weekly12m
Harry Connick Jr. Shares Rare Photo With Adult Daughters at Australian Open
Harry Connick Jr. shared a major “girl dad” moment with his three daughters at the two-week-long Australian Open in Melbourne ...